Table 4.
Variable | Code | Adjusted OR (95% CI) | P‐value |
---|---|---|---|
GM3/17 | 0: 3/3 (ref.) | ||
1: 3/17 | 1·28 (0·34–4·74) | 0·71 n.s. | |
2: 17/17 | 11·88 (0·70–202·3) | 0·08 2 | |
GM23 | 0: −/− (ref.) | ||
1: −/+ | 8·32 (1·02–67·58) | 0·04 1 | |
2: +/+ | 10·85 (0·97–121·57) | 0·05 2 | |
KIR2DS2 | 0: absent | ||
1: present | 0·13 (0·02–0·77) | 0·02 1 | |
KIR2DS5 | 0: absent | ||
1: present | 4·99 (0·99–25·15) | 0·05 2 | |
HLA‐C2 | 0: absent | ||
1: present | 3·57 (1·13–11·30) | 0·03 1 | |
HLA‐Bw4T | 0: Absent | ||
1: Present | 3·42 (0·88–13·20) | 0·07 2 |
We report the following degree of evidence against the null hypothesis: 1statistical significance (P < 0·05); 2weak statistical significance (P < 0·10); n.s., not significant. TThreonine.